pfizer paxlovid news - Search News

Pfizer, Paxlovid

The Associated Press on MSN · 21h

Pfizer rides Paxlovid sales growth to better-than-expected third quarter

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year.

Hosted on MSN · 18h

Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase

Pfizer PFE reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 cents per share. The company had recorded an adjusted loss of 17 cents per share in the year-ago quarter.

Benzinga.com · 23h

Pfizer Q3 Earnings: Revenue And Profit Beat On Heightened Demand For Paxlovid, Expects $10 Billion In 2024 Revenue From COVID Products

Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, Comirnaty, and Seagen contributions.

Pfizer CEO defends turnaround strategy

CNBC on MSN · 12h

Pfizer CEO says he welcomes good ideas as Starboard ups pressure on company

Pfizer reported an earnings beat Tuesday morning and raised its full-year outlook, seeing strength in sales of its Covid vaccine and antiviral pill, Paxlovid.

Reuters on MSN · 17h

Pfizer CEO defends turnaround strategy as activist pressures management

By Michael Erman and Bhanvi Satija (Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding after it reported a higher-than-expected profit due to strong sales of COVID-19 treatment Paxlovid.

Barron's on MSN · 15h

Pfizer CEO Defends Record Against Activist Attack

Pfizer shares have performed abysmally in recent years, as the company has failed to win investor confidence ahead of a wave of patent expirations coming by the end of the decade.

Crain's New York1h

Pfizer CEO, under fire, will do ‘whatever it takes’ to grow

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...

devdiscourse20h

Pfizer's Paxlovid Success: A Glimmer Amidst Investor Scrutiny

Pfizer reported higher-than-expected profit due to strong sales of COVID-19 treatment Paxlovid. Despite this success, the ...

16hon MSN

Pfizer Results May Temper Efforts for Shakeup Demanded by Activist Investor

Pfizer beat third-quarter profit and sales forecasts and raised its guidance on strong sales of its COVID-19 treatment.

17hon MSN

Why is Pfizer stock falling after Q3 results?

Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...

devdiscourse18h

Pfizer's Paxlovid Powers Profit Surge Amidst Activist Pressure

Pfizer reported higher-than-expected profits driven by strong Paxlovid sales, offsetting a decline in COVID vaccine sales.

9h

Pfizer’s Hold Rating Maintained Amid Unsustainable Surprises and Limited Growth Prospects

Analyst Chris Schott from J.P. Morgan maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results